NOGA Therapeutics BIOMED 2022 Abstract

- **Investment Rational**

  NOGA Therapeutics is a preclinical biotech developing a next generation in-vivo gene delivery platform. Our platform will offer an affordable, effective, and off-the-shelf solution. Backed by a strong partnership with LONZA-AG, and a cutting-edge synthetic biology approach, we aim to generate target specific, hypoimmunogenic lentiviral vectors. These novel vectors will unlock a wide range of possibilities in gene therapy medicine.

- **Business Strategy**

  In the short term, NOGA will partner with a pharma company for the clinical development of our first product NTX001, an ex-vivo lentiviral gene therapy for X-linked agammaglobulinemia (XLA). In the long term, NOGA will apply a proprietary lentiviral vector platform to generate a pipeline of in vivo LV products.

  Core Technology

  NOGA is enabling the transition from the current inaccessible, customized ex-vivo lentiviral vector process to an off-the-shelf injectable solution. Our solution, the Lent-Me-In ™ platform, is designed to resolve the main bottlenecks for in-vivo LV administration, significantly reducing costs and treatment associated risks. The hypoimmunogenic, target specific LVs are designed to evade innate and adaptive immune responses, allowing therapy re-administration.

- **Product Profile/Pipeline**

  NTX001, is an ex-vivo lentiviral gene therapy for XLA, an indication with a target addressable market of $3B. We have shown safety and efficacy of our vector in an XLA mouse model and human cells, towards a phase 1/2 in Q1-2024. Our pipeline also includes two additional in-vivo indications in discovery phase, namely SCID-X1 and type I diabetes.

- **What's Next?**

  R&D- In the coming 12-18 months we will:

  - Generate a POC of the Lent-Me-In ™ in a humanized mouse model
  - File patent applications to protect unique features of the Lent-Me-In ™ system.
  - Strengthen our POC of NTX001 using XLA patient cells

  Financing- we are gearing up to initiate a series A financing round during this period